⌕
10x Genomics · TXG · Nasdaq
Tenet 51 · Mixed
Compare
$54.99−5.50%At closeTenet 51 · Mixed
$54.99−3.20 (−5.50%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

10x Genomics (TXG) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire…

● Zacks Investment ResearchNov 12, 2026 · 14:30 ET
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study

TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.…

● PRNewsWireNov 10, 2026 · 09:00 ET
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science tec…

● MarketBeatNov 8, 2026 · 21:14 ETEARNINGS EXPECTED BY FEB 2
What Torex Gold Resources (TXG) Said on Its Q3 Earnings Call

Torex Gold Resources TSE: TXG reported a 37% quarter-over-quarter increase in production in the third quarter of 2026, as higher grades and improved gold recovery boosted margins and cash flow at its Morelos complex.…

● Defense WorldNov 8, 2026 · 03:41 ETEARNINGS EXPECTED BY FEB 2
10x Genomics $TXG Stock: Chicago Partners Investment Group LLC Lowers Position

Chicago Partners Investment Group LLC lowered its position in shares of 10x Genomics (NASDAQ: TXG) by 29.3% in a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang…

● Zacks Investment ResearchNov 6, 2026 · 12:55 ET
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis

TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.…

● Zacks Investment ResearchNov 6, 2026 · 11:36 ETEARNINGS EXPECTED BY FEB 2
TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook

10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.…

● MarketBeatNov 6, 2026 · 09:15 ETEARNINGS EXPECTED BY FEB 2
What 10x Genomics (TXG) Said on Its Q3 Earnings Call

10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.…

● Zacks Investment ResearchNov 5, 2026 · 20:31 ETEARNINGS EXPECTED BY FEB 2
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the ye…

● Seeking AlphaNov 5, 2026 · 20:24 ETEARNINGS EXPECTED BY FEB 2
10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 5, 2026 · 18:46 ETEARNINGS EXPECTED BY FEB 2
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.22 per share a year ago.…

● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
10x Genomics Reports Third Quarter 2026 Financial Results

PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the t…

● PRNewsWireNov 2, 2026 · 09:00 ETCOMPANY'S OWN WORDS
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis

Powered by Anthropic's Claude, Sentira Single Cell enables researchers to analyze Chromium data using natural language, accelerating the path from scientific questions to experimental conclusions PLEASANTON, Calif., Nov.…

● Zacks Investment ResearchOct 30, 2026 · 11:11 ET
3 Promising Genomics Stocks to Add to Your Portfolio Now

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.…

● PRNewsWireOct 27, 2026 · 16:05 ETCOMPANY'S OWN WORDS
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference

PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that members of its manag…

● GuruFocusOct 16, 2026 · 18:47 ET
A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86

On October 16, 2026, 10x Genomics Inc (TXG) shares fell 3.5%, bringing the current price to $69.86. The stock has experienced significant price fluctuations, wi…

● PRNewsWireOct 13, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 2
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial result…

● Zacks Investment ResearchOct 8, 2026 · 11:26 ET
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.…

● PRNewsWireOct 7, 2026 · 09:00 ETCOMPANY'S OWN WORDS
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /P…

● Zacks Investment ResearchSep 30, 2026 · 13:11 ET
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.…

● PRNewsWireSep 29, 2026 · 09:01 ETCOMPANY'S OWN WORDS
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEASANTON, Calif., Sept…

● PRNewsWireSep 29, 2026 · 09:00 ETCOMPANY'S OWN WORDS
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x G…

● PRNewsWireSep 10, 2026 · 09:00 ET
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, …

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 2. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just TXG · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.